Summary
On 8 October, New Zealand's a2 Milk Company held a product launch at its a2 Pokeno integrated nutrition manufacturing facility on New Zealand's North Island, unveiling two new infant formula products for the Chinese market and announcing continued investment in product innovation and quality systems in China. David Bortolussi, Managing Director and Chief Executive Officer of a2 Milk Company, spoke at the launch. Dairy is a pillar of China-New Zealand trade and economic co-operation, and New Zealand has long ranked among the top sources of China's dairy imports.
According to company executives, a2 Milk holds more than 130 related patents globally around A2-type protein; the raw milk from its supplier herds contains only A2 beta-casein and no A1 protein. The molecular structure of A2 beta-casein is closer to the natural beta-casein in human breast milk, and it is the core scientific foundation on which the company has built a full product range over 26 years. In 2013, a2 Milk Company entered the Chinese market with infant formula products through a strategic partnership with China State Farms Holdings Shanghai Co.
, Ltd. The company says it has ranked among China's top five infant formula brands since 2024.
Commentary
a2 Milk Company's latest product launch and increased investment in China reflect New Zealand dairy firms' deep reliance on the Chinese market and their strategic adjustments. As the world's largest dairy importer, China's infant formula market is undergoing structural change: a declining birth rate has slowed overall volume growth, but consumer demand for science-based nutrition and functional formulations is rising, with differentiated products such as A2-type protein becoming growth engines. With more than 130 patents and 26 years of research, a2 has become one of China's top five brands.
Its channel partnership model with China State Farms offers a reference for smaller New Zealand firms: entering complex distribution networks through local partners rather than going it alone. On the other hand, domestic Chinese brands such as Feihe and Yili are also accelerating premiumisation, and regulatory policies such as the formula registration system have raised barriers to entry. For smaller New Zealand dairy firms seeking a share, building technical barriers in niche segments (such as organic, grass-fed or specific functional products) and focusing on asset-light channels such as cross-border e-commerce will be essential.
Giants such as Fonterra still dominate ingredient supply, but branding and higher-value products are where the profit lies. a2's integrated production model at Pokeno also highlights the importance of localising supply chains to address geopolitical and logistics risks. For smaller New Zealand business owners, the window of opportunity in China has not closed, but competition has shifted from resource endowments to technological innovation and consumer insight.
Keywords: a2 Milk Company, infant formula, A2-type protein, China-New Zealand dairy co-operation, Chinese market, product launch, a2 Pokeno facility, China State Farms Holdings Shanghai Co., Ltd.
Source: CCTV International
Disclaimer: This article is compiled from publicly available sources for general information only. The analysis and commentary are editorial opinions. MiDeer Observer does not guarantee the accuracy or completeness of the information provided. Readers should seek independent professional advice before relying on this content, or contact us for more information.






